全文获取类型
收费全文 | 1776411篇 |
免费 | 135017篇 |
国内免费 | 10885篇 |
专业分类
耳鼻咽喉 | 22357篇 |
儿科学 | 56405篇 |
妇产科学 | 47070篇 |
基础医学 | 251244篇 |
口腔科学 | 50269篇 |
临床医学 | 163705篇 |
内科学 | 345178篇 |
皮肤病学 | 39306篇 |
神经病学 | 136053篇 |
特种医学 | 66890篇 |
外国民族医学 | 298篇 |
外科学 | 264972篇 |
综合类 | 53955篇 |
现状与发展 | 26篇 |
一般理论 | 543篇 |
预防医学 | 129565篇 |
眼科学 | 43045篇 |
药学 | 132458篇 |
107篇 | |
中国医学 | 10233篇 |
肿瘤学 | 108634篇 |
出版年
2021年 | 17835篇 |
2019年 | 16650篇 |
2018年 | 23267篇 |
2017年 | 17994篇 |
2016年 | 19337篇 |
2015年 | 23120篇 |
2014年 | 31350篇 |
2013年 | 42255篇 |
2012年 | 59027篇 |
2011年 | 62766篇 |
2010年 | 37188篇 |
2009年 | 34170篇 |
2008年 | 55906篇 |
2007年 | 59050篇 |
2006年 | 59722篇 |
2005年 | 57055篇 |
2004年 | 53382篇 |
2003年 | 50731篇 |
2002年 | 48489篇 |
2001年 | 93478篇 |
2000年 | 95456篇 |
1999年 | 78949篇 |
1998年 | 21085篇 |
1997年 | 18575篇 |
1996年 | 18461篇 |
1995年 | 17738篇 |
1994年 | 16118篇 |
1993年 | 14580篇 |
1992年 | 57936篇 |
1991年 | 55737篇 |
1990年 | 53394篇 |
1989年 | 51108篇 |
1988年 | 46419篇 |
1987年 | 45175篇 |
1986年 | 42408篇 |
1985年 | 40139篇 |
1984年 | 29410篇 |
1983年 | 24943篇 |
1982年 | 13933篇 |
1979年 | 25548篇 |
1978年 | 17574篇 |
1977年 | 14906篇 |
1976年 | 13874篇 |
1975年 | 14563篇 |
1974年 | 17630篇 |
1973年 | 16944篇 |
1972年 | 15673篇 |
1971年 | 14453篇 |
1970年 | 13431篇 |
1969年 | 12517篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
11.
Bortezomib is a novel proteasome inhibitor, which has been successfully used to treat mantle cell lymphoma and multiple myeloma. However, the direct effects of bortezomib on acute promyelocytic leukaemia (APL) have not been fully investigated. In the present study, the WST-8 assay, western blotting, flow cytometry, monodansylcadaverine staining and transmission electron microscopy were performed. It was demonstrated that bortezomib treatment induced a time- and dose-dependent decrease in the viability of NB4 cells. Bortezomib treatment induced cell apoptosis in NB4 cells, as assessed by Annexin V/propidium iodide analysis, and the detection of cleaved caspase-3, cleaved poly(ADP-ribose) polymerase, Bax and Bcl-2 expression. Furthermore, bortezomib treatment induced autophagy in NB4 cells, as indicated by autophagosome formation, p62 degradation, LC3-I to LC3-II conversion and formation of acidic autophagic vacuoles. Notably, autophagy induced by bortezomib was initiated prior to apoptosis. Inhibition of autophagy by knocking down Beclin-1 expression increased bortezomib-induced apoptosis in NB4 cells. Therefore, the present study revealed that the combination of bortezomib and autophagy inhibition may be a potential treatment strategy for APL. 相似文献
12.
“三全育人”视角下思政教育机制实践与探索——“杏林成长导师”计划的构建 《医学教育管理》2021,7(6):656-660
“三全育人”是高校思政教育工作的关键一环,也是中医药高校推动思政教育的重要内容。以“三全育人”为视角对北京中医药大学思想政治教育举措“杏林成长导师”计划路径、内容深入分析,运用统计分析和文献研究方法,剖析该计划对中医学专业大学生的学业、思想和实践等多个层面的现实成效,从而为“三全育人”理念在中医药院校制度建构中的应用提供新的视角与方法。 相似文献
13.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
14.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
15.
16.
Clinical & Experimental Metastasis - 相似文献
17.
18.
三阴性乳腺癌(triple negative breast cancer,TNBC)是雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)及人类表皮生长因子受体(human epidermal growth factor-2,HER-2)均不表达的乳腺癌。按其功能特征可归纳为5类分子分型:以DNA修复缺陷或生长因子为途径的基底细胞样三阴性乳腺癌;以上皮-间充质转化和肿瘤干细胞为特征的间质样三阴性乳腺癌;免疫调节型三阴性乳腺癌;雄激素受体过表达的管腔/分泌型三阴性乳腺癌;HER-2富集型三阴性乳腺癌。三阴性乳腺癌恶性程度高且异型性较大,其治疗困难且预后较差,内分泌治疗及靶向治疗不敏感。目前很多学者对于三阴性乳腺癌的治疗各有研究,并有临床试验证实下述治疗有效。 相似文献
19.
20.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献